Active Ingredient(s):Saxagliptin Hydrochloride FDA Approved: * July 31, 2009 Pharm Company: *BRISTOL MYERS SQUIBB Category:Diabetes
Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug.
In April 2016, the U.S. FDA added a warning about increased risk of heart failure. This was based on data ...
* May have multiple approval dates, manufacturers, or labelers. 3 Discussions